A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer

Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
The Journal of urology (Impact Factor: 3.75). 06/2010; 183(6):2219-26. DOI: 10.1016/j.juro.2010.02.020
Source: PubMed

ABSTRACT This phase I study of high dose ketoconazole and docetaxel was designed against castration resistant prostate cancer to determine the maximum tolerated doses, side effects, and pharmacokinetic interaction of co-administered docetaxel and ketoconazole.
Patients with metastatic castration resistant prostate cancer received weekly docetaxel for 3 of every 4 weeks plus daily ketoconazole. Pharmacokinetic studies were performed on day 1 (docetaxel alone) and day 16 (after ketoconazole).
The study enrolled 42 patients at 9 different dose levels. The combination regimens investigated included docetaxel weekly, increasing from 5 to 43 mg/m(2), with starting doses of 600, 800 or 1,200 mg ketoconazole daily. Decreases in prostate specific antigen of 50% or greater were seen in 62% of patients. Of 25 patients with soft tissue disease 7 (28%) had a partial response. Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001). The most frequently observed adverse events were anemia, edema, fatigue, diarrhea, nausea, sensory neuropathy and elevated liver function tests. The fractional change in docetaxel clearance correlated significantly with ketoconazole exposure (p <0.01). Concomitant ketoconazole increased docetaxel exposure 2.6-fold with 1,200 mg daily, 1.6-fold with 800 mg daily and approximately 1.3 to 1.5-fold with 600 mg daily.
Combination regimens using 600 mg ketoconazole daily were fairly well tolerated and the maximum tolerated dose of docetaxel was 32 mg/m(2). Results suggest that the combination has significant antitumor activity in castration resistant prostate cancer. The long survival in the docetaxel naïve cohort warrants additional, larger trials of docetaxel with ketoconazole or possibly CYP17A1 inhibitors such as abiraterone.

Download full-text


Available from: James L Gulley, Jan 15, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Modern design evaluation technologies based on human figure simulations are helping us to make fuller and more accurate assessments of human/machine and workplace interfaces. As computer graphics and related digital technologies advance, one will be able to illustrate, predict, evaluate, and document a wider array of human performance issues involving system useability concurrently with design development. The Design Evaluation for Personnel, Training, and Human Factors (DEPTH) program is developing and integrating many of these technologies for engineering applications. This paper provides an overview of current and planned DEPTH technology developments
    Aerospace and Electronics Conference, 1994. NAECON 1994., Proceedings of the IEEE 1994 National; 06/1994
  • [Show abstract] [Hide abstract]
    ABSTRACT: An electronics engineer is about to visit a country in another continent where he hopes to sell communications technology. Before departure, he seeks advice about that culture from a colleague from a neighboring country who has done business there. When he arrives, he finds that none of the advice makes sense. Why? A group of Western executives visits an East-European country to arrange a joint manufacturing venture. It includes a native speaker who emigrated to the West forty years ago. Whenever he is present at various meetings communication breaks down. What is going on? The author explains how, when these and other incidents are analyzed, one realizes how one culture's perception of another is clouded by its own perception system. Statements about other cultures often reveal more about the people making them than they do about the foreign cultures in question. He details how there are various levels of understanding that need to be reached for effective cross-cultural communication
    Engineering Management Conference, 1994. 'Management in Transition: Engineering a Changing World', Proceedings of the 1994 IEEE International; 11/1994
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer (PC) is now the second most prevalent cause of death in men in the USA and Europe. At present, the major treatment options include surgical or medical castration. These strategies cause ablation of the production of testosterone (T), dihydrotestosterone (DHT) and related androgens by the testes. However, because these procedures do not affect adrenal, prostate and other tissues' androgen production, they are often combined with androgen receptor antagonists to block their action. Indeed, recent studies have unequivocally established that in castration-resistant prostate cancer (CRPC) many androgen-regulated genes become re-expressed and tissue androgen levels increase despite low serum levels. Clearly, inhibition of the key enzyme which catalyzes the biosynthesis of androgens from pregnane precursors, 17α-hydroxy/17,20-lyase (hereafter referred to as CYP17) could prevent androgen production from all sources. Thus, total ablation of androgen production by potent CYP17 inhibitors may provide effective treatment of prostate cancer patients. This review highlights the role of androgen biosynthesis in the progression of prostate cancer and the impact of CYP17 inhibitors, such as ketoconazole, abiraterone acetate, VN/124-1 (TOK-001) and TAK-700 in the clinic and in clinical development. Article from the special issue on Targeted Inhibitors.
    The Journal of steroid biochemistry and molecular biology 11/2010; 125(1-2):23-31. DOI:10.1016/j.jsbmb.2010.11.005 · 4.05 Impact Factor
Show more